

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10577688
Filing Date	2006-04-28
First Named Inventor	Yoshida et al
Art Unit	1646
Examiner Name	
Attorney Docket Number	TESHP103US

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5547939		1996-08-20	Selsted	
	2	5807746		1998-09-15	Lin et al	
	3	5877282		1999-03-02	Nadler et al	
	4	5962415		1999-10-05	Nadler	
	5	6043339		2000-03-28	Lin et al	
	6	6180604		2001-01-30	Fraser et al	
	7	6191254		2001-02-20	Falla et al	
	8	6303575		2001-10-16	Selsted	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10577688
Filing Date	2006-04-28
First Named Inventor	Yoshida et al
Art Unit	1646
Examiner Name	
Attorney Docket Number	TESHP103US

9	6476189		2002-11-05	Yamakawa et al	
10	5789542		1998-08-04	McLaughlin et al	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020137685		2002-09-26	Catania et al	
	2	20030129156		2003-07-10	Lipton et al	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0236612	WO		2002-05-10	Cambridge University		<input type="checkbox"/>
	2	11-71399A	JP		1999-03-16	Carlos Adriel Dell Calpio et al		<input checked="" type="checkbox"/>
	3	0208266	WO		2002-01-31	Pharmacia & UpJohn Company		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10577688
Filing Date		2006-04-28
First Named Inventor	Yoshida et al	
Art Unit	1646	
Examiner Name		
Attorney Docket Number	TESHP103US	

4	0294868	WO		2002-11-28	Chiron Spa		<input type="checkbox"/>
5	9851794	WO		1998-11-19	Human Genome Sciences		<input type="checkbox"/>
6	9926971	WO		1999-06-03	University of Melbourne		<input type="checkbox"/>
7	0009553	WO		2000-02-24	Bionebraska Inc		<input type="checkbox"/>
8	0059527	WO		2000-10-12	Zengen Inc		<input type="checkbox"/>
9	0109175	WO		2001-02-08	Zeneca Limited		<input type="checkbox"/>
10	2000-63400	JP		2000-02-29	National Institute of Sericultural & Entomological		<input checked="" type="checkbox"/>
11	2001-186887	JP		2001-07-10	Suntory Ltd		<input checked="" type="checkbox"/>
12	9402610	WO		1994-02-03	Dana Farber Cancer		<input type="checkbox"/>
13	9636692	WO		1996-11-21	The Regents of the University of CA		<input type="checkbox"/>
14	9929721	WO		1999-06-17	Washington University		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10577688
Filing Date	2006-04-28
First Named Inventor	Yoshida et al
Art Unit	1646
Examiner Name	
Attorney Docket Number	TESHP103US

15	9967284	WO		1999-12-29	Washington University	<input type="checkbox"/>
16	0210201	WO		2002-02-07	Active Motif	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	GHOSH, A., et al., Isolation of a laminin-binding protein from the protozoan parasite Leishmania donovani that may mediate cell adhesion, Biochem J, (1999) Vol. 337, No. 3, p. 551-8.	<input type="checkbox"/>
	2	ARDINI, E., et al., The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution, Mol Biol Evol, (1998) Vol. 15, No. 8, p. 1017-25.	<input type="checkbox"/>
	3	BANDYOPADHYAY, K., et al., Role of 67 kDa cell surface laminin binding protein of Leishmania donovani in pathogenesis, J Biochem (Tokyo), (2001)Vol. 130, No. 1, p. 141-8.	<input type="checkbox"/>
	4	VALKONEN, K. H., et al., Binding of basement-membrane laminin by Escherichia coli, Mol Microbiol, (1991) Vol. 5, No. 9, p. 2133-41.	<input type="checkbox"/>
	5	CASTRONOVO, V., et al., Functional domains of the 67-kDa laminin receptor precursor, J Biol Chem, (1991) Vol. 266, No. 30, p. 20440-6.	<input type="checkbox"/>
	6	Nahoko KOBAYASHI et al., "Molecular Design of Peptide-based Antimicrobial Agent," The Society for Antibacterial and Antifungal Agents, Japan, Abstracts of the Meeting, (2003. 05. 25), Vol. 30, Page 137, IIDp-5 w/English translation	<input checked="" type="checkbox"/>
	7	PEI, L., et al., Functional studies of a fibrinogen binding protein from Staphylococcus epidermidis, Infect Immun, (1999) Vol. 67, No. 9, p. 4525-30.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10577688
	Filing Date		2006-04-28
	First Named Inventor	Yoshida et al	
	Art Unit	1646	
	Examiner Name		
	Attorney Docket Number	TESHP103US	

8	Mariagrazia Cutuli et al., "Antimicrobial effects of a-MSH peptides," Journal of Leukocyte Biology, Volume 67, February 2000, pp. 233-239.	<input type="checkbox"/>
9	Richards DB et al., "Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit," Peptides, 1984 Jul-Aug; 5(4): 815-7, Abstract, PubMed.	<input type="checkbox"/>
10	Laure Beven et al., "Effects on mollicutes (wall-less bacteria) of synthetic peptides comprising a signal peptide or a membrane fusion peptide, and a nuclear localization sequence (NLS) - a comparison with melittin," Biochim Biophys Acta 1997 Oct. 23:1329(2), pp 357-369.	<input type="checkbox"/>
11	Laurent Chaloin et al., "Ionic channels formed by a primary amphipathic peptide containing a signal peptide and a nuclear localization sequence," Biochim biophys Acta 1998 Oct. 15: 1375(1-2), pp 52-60	<input type="checkbox"/>
12	Shai, Yechiel, "From Innate Immunity to de-Novo Designed Antimicrobial Peptides," Current Pharmaceutical Design, 2002, Vol. 8, pp. 715-725	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10577688
Filing Date	2006-04-28
First Named Inventor	Yoshida et al
Art Unit	1646
Examiner Name	
Attorney Docket Number	TESHP103US

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Greg Turocy/	Date (YYYY-MM-DD)	2006-10-24
Name/Print	Gregory Turocy	Registration Number	36952

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.